The content on this site is intended for healthcare professionals only
Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
21 Jun 2021
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL
Prof John Allan - Weill Cornell Medicine, New York, USA
17 Jun 2021
Interim results of a phase II study of blinatumomab plus ponatinib for Philadelp...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
17 Jun 2021
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leuka...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
17 Jun 2021
EHA 2021: Latest in immunotherapy for R/R multiple myeloma
Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cav...
17 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
15 Jun 2021
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL
Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlan...
15 Jun 2021
Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma
Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark
15 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
14 Jun 2021
Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-...
Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA
11 Jun 2021
